% | $
Quotes you view appear here for quick access.

Apricus Biosciences, Inc. Message Board

  • adiianni Feb 10, 2013 8:21 AM Flag

    New OTC pruduct from Apricus Bioscience

    PsoriaVa™ (Calcipotriene/Betamethasone and DDAIP for the treatment of Psoriasis; Pre-IND)
    Long term safety and efficacy continues to be elusive with psoriasis treatments. In a pre-clinical efficacy study, PsoriaVa™ delivered the same level of drugs as Taclonex® (Calcipotriene 0.005%/Betamethasone 0.64%). In a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that PsoriaVa™ significantly lowered clinical inflammation and erythema scores in sick animals potentially achieving similar efficacy with superior safety to currently available therapies.

    Sentiment: Strong Buy

1.16-0.01(-0.85%)1:12 PMEST